EUVIMEDSkopri EUVIMED
EUVIMED · CrossrefJournal

Cancer Research and Treatment

ISSN 1598-2998 · Korean Cancer Association

Latest articles

  1. A Nationwide Study of Interobserver Agreement and Accuracy in HER2 Immunohistochemistry and the Impact of Artificial Intelligence on HER2 Interpretation

    Hyunwoo Lee, Gyu Young Kim, Yoon Ah Cho, Gyungyub Gong, Hee Jin Lee, Byung-Kwan Jeong, Ji‐Seon Jeong, Young Kyung Bae, Min Chong Kim, So Yeon Park, Jiwon Koh, Jee Yeon Kim, Ho-Chang Lee, Hee Sung Kim, Wan Seop Kim, Young Hee Maeng, Sun Young Kwon, Chungyeul Kim, Sun-Young Jun, Hye Jeong Choi, Somang Lee, Nora Jee-Young Park, Ae Ri Ahn, Hyun Joo Choi, Jeong Yun Shim, Ji-Young Kim, Su Jung Kum, Hyang Im Lee, Song-Hee Han, Youjeong Seo, Yoon Jin Cha, Junjeong Choi, Yo Han Jeon, Ji Min Na, Miseon Lee, Hera Jung, Yeonjin Jeon, Jinye Yoo, Gui Young Kwon, Eun Yoon Cho

    Published: 2026-11-02DOI: 10.4143/crt.2026.0805

  2. Pyrotinib Plus Trastuzumab and Docetaxel with Different Antidiarrheal Strategies in Patients with HER2-Positive Recurrent or Metastatic Breast Cancer (PHAENNA): A Multicenter, Phase 1 Trial

    Wei Ren, Xiuping Lai, Guiying Bai, Yanqiong Liu, Hongtao Li, Huan Zhou, Shouman Wang, Qun Qin, Wei Li, Cuizhi Geng, Mingxia Wang, Xinshuai Wang, Yu Cao, Zhuang Yu, Caiwen Du, Wei Zhao, Shikai Wu, Yimin Cui, Pan Liu, Kaijing Zhao, Jiaman Lin, Xiaoyu Zhu, Yandan Yao, Yehui Shi, Herui Yao

    Published: 2026-07-28DOI: 10.4143/crt.2026.0400

Volumes

2026 · 1712025 · 1692024 · 1202023 · 1302022 · 1212021 · 1262020 · 1202019 · 1632018 · 1422017 · 1202016 · 1622015 · 462014 · 1122013 · 462012 · 422011 · 422010 · 402009 · 412008 · 382007 · 352006 · 412005 · 592004 · 652003 · 832002 · 742001 · 481970 · 15

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.